Literature DB >> 24668343

In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes.

Nadine Hagelauer1, Andreas Max Pabst, Thomas Ziebart, Holger Ulbrich, Christian Walter.   

Abstract

OBJECTIVES: Bisphosphonate-associated osteonecrosis of the jaws is a serious side effect that mainly occurs in patients receiving highly potent, nitrogen-containing bisphosphonates. Usually the diagnosis is made due to exposed bone and a nonhealing wound. Neutrophil granulocytes are essential for sufficient wound healing; therefore, the influence of different bisphosphonates on neutrophil granulocytes was the focus of this study.
MATERIAL AND METHODS: The effect of nitrogen-containing bisphosphonates (ibandronate, pamidronate, and zoledronate) and one non-nitrogen-containing bisphosphonate (clodronate) on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes in human whole blood was analyzed using standard cytometric flow assays.
RESULTS: Chemotaxis of neutrophils was reduced by almost 50 % when cells were treated with ibandronate and zoledronate. All tested nitrogen-containing bisphosphonates moderately increased the percentage of phagocytizing neutrophils, whereas the percentage of oxidizing cells was extremely affected. Zoledronate increased the oxidative burst activity even at low concentrations. Treatment with ibandronate and pamidronate reached the same level, but only in at least 10 times the higher concentrations. The maximal burst activity of a single cell reached nearly 150 % compared to control. In this case, zoledronate also caused maximal effects even at low concentrations. Clodronate did not show any effects.
CONCLUSION: The results show a proinflammatory effect of the nitrogen-containing effect on neutrophil granulocytes which might contribute to the development of osteonecrosis. CLINICAL RELEVANCE: The altered neutrophil defense might play a key role in the pathogenesis of bisphosphonate-associated osteonecrosis of the jaws, although the underlying causation between inflammatory reaction and the development of necrosis is yet unknown.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24668343     DOI: 10.1007/s00784-014-1219-0

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.573


  47 in total

Review 1.  Wound healing: an overview.

Authors:  George Broughton; Jeffrey E Janis; Christopher E Attinger
Journal:  Plast Reconstr Surg       Date:  2006-06       Impact factor: 4.730

2.  CC chemokines induce neutrophils to chemotaxis, degranulation, and alpha-defensin release.

Authors:  Ming-Shiou Jan; Yi-Hsien Huang; Biehuoy Shieh; Ru-Hsiu Teng; Yao-Pei Yan; Yuan-Ti Lee; Ko-Kaung Liao; Ching Li
Journal:  J Acquir Immune Defic Syndr       Date:  2006-01-01       Impact factor: 3.731

3.  The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study.

Authors:  Andreas M Pabst; Thomas Ziebart; Felix P Koch; Katherine Y Taylor; Bilal Al-Nawas; Christian Walter
Journal:  Clin Oral Investig       Date:  2011-01-12       Impact factor: 3.573

4.  Zoledronate and pamidronate depress neutrophil functions and survival in mice.

Authors:  J W P Kuiper; C Forster; C Sun; S Peel; M Glogauer
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

Review 5.  Novel aspects of mevalonate pathway inhibitors as antitumor agents.

Authors:  Martin Thurnher; Oliver Nussbaumer; Georg Gruenbacher
Journal:  Clin Cancer Res       Date:  2012-04-23       Impact factor: 12.531

6.  Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro.

Authors:  C Walter; A Pabst; T Ziebart; Mo Klein; B Al-Nawas
Journal:  Oral Dis       Date:  2010-08-27       Impact factor: 3.511

7.  Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells.

Authors:  C Walter; M O Klein; A Pabst; B Al-Nawas; H Duschner; T Ziebart
Journal:  Clin Oral Investig       Date:  2009-03-18       Impact factor: 3.573

8.  Radiologic bone loss in patients with bisphosphonate-associated osteonecrosis of the jaws: a case-control study.

Authors:  Christian Walter; Christian Laux; Keyvan Sagheb
Journal:  Clin Oral Investig       Date:  2013-03-23       Impact factor: 3.573

9.  The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins.

Authors:  R E Hewitt; A Lissina; A E Green; E S Slay; D A Price; A K Sewell
Journal:  Clin Exp Immunol       Date:  2005-01       Impact factor: 4.330

Review 10.  Vgamma9Vdelta2 T cell-mediated non-cytolytic antiviral mechanisms and their potential for cell-based therapy.

Authors:  Fabrizio Poccia; Chiara Agrati; Federico Martini; Gloria Mejia; Marianne Wallace; Miroslav Malkovsky
Journal:  Immunol Lett       Date:  2005-08-15       Impact factor: 3.685

View more
  17 in total

1.  Bisphosphonates inhibit cell functions of HUVECs, fibroblasts and osteogenic cells via inhibition of protein geranylgeranylation.

Authors:  Nadine Hagelauer; Thomas Ziebart; Andreas M Pabst; Christian Walter
Journal:  Clin Oral Investig       Date:  2014-09-27       Impact factor: 3.573

2.  Isoprenoid geranylgeraniol: the influence on cell characteristics of endothelial progenitor cells after bisphosphonate therapy in vitro.

Authors:  A M Pabst; M Krüger; T Ziebart; C Jacobs; C Walter
Journal:  Clin Oral Investig       Date:  2015-01-16       Impact factor: 3.573

Review 3.  Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw.

Authors:  J Chang; A E Hakam; L K McCauley
Journal:  Curr Osteoporos Rep       Date:  2018-10       Impact factor: 5.096

4.  The influence of geranylgeraniol on microvessel sprouting after bisphosphonate substitution in an in vitro 3D-angiogenesis assay.

Authors:  A M Pabst; M Krüger; K Sagheb; T Ziebart; C Jacobs; S Blatt; E Goetze; C Walter
Journal:  Clin Oral Investig       Date:  2016-05-12       Impact factor: 3.573

5.  Mechanical loading increases pro-inflammatory effects of nitrogen-containing bisphosphonate in human periodontal fibroblasts.

Authors:  Collin Jacobs; Sabrina Schramm; Isabelle Dirks; Christian Walter; Andreas Pabst; Dan Meila; Cornelius Jacobs; Heinrich Wehrbein
Journal:  Clin Oral Investig       Date:  2017-07-07       Impact factor: 3.573

6.  Periosteal microcirculatory reactions in a zoledronate-induced osteonecrosis model of the jaw in rats.

Authors:  Ágnes Janovszky; Andrea Szabó; Renáta Varga; Dénes Garab; Mihály Boros; Csilla Mester; Nikolett Beretka; Tamás Zombori; Hans-Peter Wiesmann; Ricardo Bernhardt; Imre Ocsovszki; Péter Balázs; József Piffkó
Journal:  Clin Oral Investig       Date:  2014-10-30       Impact factor: 3.573

7.  Zoledronate but not denosumab suppresses macrophagic differentiation of THP-1 cells. An aetiologic model of bisphosphonate-related osteonecrosis of the jaw (BRONJ).

Authors:  Sebastian Hoefert; Claudia Sade Hoefert; Marc Albert; Adelheid Munz; Martin Grimm; Hinnak Northoff; Siegmar Reinert; Dorothea Alexander
Journal:  Clin Oral Investig       Date:  2014-11-21       Impact factor: 3.573

8.  Altered macrophagic THP-1 cell phagocytosis and migration in bisphosphonate-related osteonecrosis of the jaw (BRONJ).

Authors:  Sebastian Hoefert; Claudia Sade Hoefert; Adelheid Munz; Hinnak Northoff; Anna Yuan; Kathrin Reichenmiller; Siegmar Reinert; Martin Grimm
Journal:  Clin Oral Investig       Date:  2015-09-09       Impact factor: 3.573

Review 9.  Macrophage Involvement in Medication-Related Osteonecrosis of the Jaw (MRONJ): A Comprehensive, Short Review.

Authors:  Ioannis Gkouveris; Akrivoula Soundia; Panagiotis Gouveris; Dionysia Zouki; Danny Hadaya; Sotirios Tetradis
Journal:  Cancers (Basel)       Date:  2022-01-10       Impact factor: 6.575

10.  Diabetes Mellitus and Its Association to the Occurrence of Medication-Related Osteonecrosis of the Jaw.

Authors:  Roman K Rahimi-Nedjat; Keyvan Sagheb; Andreas Pabst; Lukas Olk; Christian Walter
Journal:  Dent J (Basel)       Date:  2016-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.